There were 696 press releases posted in the last 24 hours and 154,047 in the last 365 days.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutics Pipeline Review, H1 2019: Indications, Stage of Development, MoA, RoA and Molecule Type

/EIN News/ -- Dublin, April 17, 2019 (GLOBE NEWSWIRE) -- The "Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report 'Integrin Beta 7 - Pipeline Review, H1 2019' outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 3 respectively.

Report covers products from therapy areas Gastrointestinal, Immunology, Infectious Disease and Undisclosed which include indications Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS) and Unspecified.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
  4. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
  5. Products under Development by Stage of Development
  6. Products under Development by Therapy Area
  7. Products under Development by Indication
  8. Products under Development by Companies
  9. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development

  • C4X Discovery Holdings PLC
  • Genentech Inc
  • Morphic Therapeutic Inc
  • Protagonist Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles

  • ET-3764 - Drug Profile
  • etrolizumab - Drug Profile
  • PN-943 - Drug Profile
  • Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
  • Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified Indication - Drug Profile
  • Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
  • vedolizumab - Drug Profile

Featured News & Press Releases

  • Mar 11, 2019: Takeda's Entyvio achieves superior remission than Humira in ulcerative colitis
  • Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head
  • Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials
  • Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
  • Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease
  • Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan
  • Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire
  • Oct 22, 2018: Investigational subcutaneous formulation of Vedolizumab achieves and maintains clinical remission and mucosal healing at Week 52 in patients with moderately to severely active Ulcerative Colitis
  • Oct 08, 2018: New real-world data analyses support the long-term use of Entyvio (Vedolizumab) in bio-nave patients for the treatment of moderate to severe ulcerative colitis or crohn's disease
  • Jul 19, 2018: Takeda reports positive top-line outcomes from VISIBLE 1 trial
  • Jul 18, 2018: Takeda Submits an Application for a New Indication of Entyvio (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Crohn's Disease in Japan
  • Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan
  • Jun 05, 2018: Analysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohn's disease patients
  • Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
  • May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ncwzo2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

22157.jpg


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.